LOGIN  |  REGISTER
C4 Therapeutics

Zynex to Present at the HC Wainwright Global Investment Conference

September 04, 2024 | Last Trade: US$8.20 0.02 -0.24

ENGLEWOOD, Colo., Sept. 4, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming HC Wainwright Global Investment Conference, which is being held September 9-11, 2024.

Zynex's fireside chat will be held in person and webcast live on September 10 at 11:30 AM ET at the Lotte New York Palace Hotel in New York, NY. You can listen to the webcast at Webcast Link. Dan Moorhead, CFO, will be available for one-on-one meetings on September 9 and 10.

To receive additional information, register to attend, or schedule a one-on-one meeting, email This email address is being protected from spambots. You need JavaScript enabled to view it.

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594

Astria Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB